Recently, many biomarkers, such as single-cell RNA sequencing or non-targeted metabolomics from tumor samples, and immune infiltration in the tumor microenvironment, had been shown to be potentially useful to predict therapeutic response in lung cancer patients treated with anti-PD-1 immunotherapy (57, 58). This evidence concerns the gene PDCD1 and neoplasm.